The National Toxicology Program study of Ginkgo biloba extract (GBE), a herbal supplement, reported concerns regarding genotoxicity and clear evidence of hepatocarcinogenicity and liver hypertrophy in mice. To clarify the genotoxicity of GBE in vivo, we performed reporter gene mutation assay using gpt delta mice. We also used a combined liver comet assay and bone marrow micronucleus assay using C3H-derived constitutive androstane receptor knockout (CARKO) and wild-type mice. No remarkable increases in gpt or Spi − mutation frequencies were observed in DNA extracted from the livers of gpt delta mice that had been exposed to GBE up to 2000 mg/kg bw/day. In the comet and micronucleus assays, no statistically significant increases in positive cells were observed at doses up to 2000 mg/kg bw/day of GBE in either mouse genotype. The present study provides clear evidence that GBE is not genotoxic in vivo. Our results indicate that GBE-induced hepatocarcinogenesis in mice occurs through a non-genotoxic mode of action.
Ginkgo biloba extract (GBE) has antioxidant and neuroprotective properties, and it has been used for a variety of medicinal purposes (Chan et al., 2007) . In Japan and the United States, GBE has also been used as a herbal supplement. Although GBE has been widely used, there have been insufficient studies regarding its potential for genotoxicity and carcinogenicity. Recently, a National Toxicology Program (NTP) study reported the results of two genotoxic assays in vitro and in vivo. In a bacterial gene mutation assay (Ames assay), GBE was mutagenic in Salmonella typhimurium strains, TA98 and TA100, and the Escherichia coli strain, Wp2 uvrA/pKM101, with and without S9 mix (NTP, 2013) . In a peripheral blood micronucleus assay in male and female mice administered GBE for 13 weeks, GBE was negative in males but judged to be equivocal in females because of positive results in a significant trend test (NTP, 2013) . Based on these results, GBE was suspected to have genotoxic potential. Furthermore, the NTP 2-year study of GBE reported significant increases in the incidence of hepatocellular adenoma/carcinoma and hepatoblastomas in B6C3F1 mice of both sexes at the lowest dose tested (200 mg/kg bw/day) and showed dose dependency, indicating clear evidence of hepatocarcinogenicity in mice (NTP, 2013) . Consequently, GBE is suspected to be a hepatocarcinogen with genotoxicity. Theoretically, genotoxic carcinogens have no dose threshold for their carcinogenic potential. Therefore, clarification of in vivo genotoxicity of GBE is a critical issue for human cancer risk assessment.
Other treatment-related changes based on short-and longterm studies in the NTP study showed that GBE increased liver weights and induced centrilobular hepatocyte hypertrophy in rats and mice (NTP, 2013) . The pattern of GBE-mediated liver hypertrophy indicated that the mode of action might involve the constitutive androstane receptor (CAR). CAR is a nuclear receptor that plays critical roles in regulating enzymes involved in xenobiotic metabolism and has a key role in liver tumor formation in rodents (Ueda et al., 2002; Wei et al., 2000; Yamamoto et al., 2004) . Therefore, we investigated CAR involvement in liver carcinogenesis by GBE using C3H-derived CAR knockout (CARKO) mice. However, it is unknown whether the sensitivity to GBE genotoxicity differs between CARKO and C3H (wildtype) mice. Hence, using both wild-type mice and CARKO mice should provide useful information regarding the genotoxicity of GBE.
In the present study, we investigated the in vivo genotoxicity of GBE using several methods. To clarify the genomic mutation potential in the liver, we performed gene mutation assays using gpt delta mice treated with GBE for 90 days. To evaluate the potential induction of DNA damage and chromosomal aberration, we carried out a combined liver comet assay and bone marrow micronucleus assay using wild-type and CARKO mice administrated GBE for 3 days. We used GBE of the same lot used in the NTP 2-year study. A dose level of 2000 mg/kg/day was se-GENOTOXICITY OF GBE 299 lected as the maximal dose because it induced liver tumors in the 2-year study of mice.
MATERIALS AND METHODS

Chemicals and Dose Volumes
The GBE used in the present study was from the same lot used for the NTP 2-year study. It was a gift provided by the National Institute of Environmental Health Sciences (North Carolina, USA). This GBE was produced by Shanghai Xing Ling Science and Technology Pharmaceutical Company, Ltd (Shanghai, China). A positive control compound used in the comet assay and the micronucleus assay, ethyl methanesulfonate (EMS; CAS 62-50-10), was purchased from Invitrogen. EMS was diluted in saline at the day of administration. Test agents were dosed at a volume of 10 ml/kg body weight, based on body weight at the day of the administration.
Animals
Male B6C3F1 gpt delta mice carrying 80 tandem copies of the transgene lambda EG10 in a haploid genome were raised by mating C57BL/6 gpt delta and nontransgenic C3H/He mice (Japan SLC, Inc., Shizuoka, Japan). C3H/HeNCrl background CARKO mice were generously provided by Dr M. Negishi, National Institute of Environmental Health Sciences, NC (Kodama et al. 2004; Yamamoto et al. 2004) . C3H/HeNCrlCrlj mice were purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan) and used as wild-type mice in the experiment 2 study. All protocols were approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences, and all studies followed the guidelines for the use of laboratory animals of the National Institute of Health Sciences.
Experiment 1: 90-Day-Repeated Dose Test Using B6C3F1 gpt
Delta Mice Study design. Six-week-old male B6C3F1 mice were divided into four groups consisting of 10 mice per group. GBE was administered daily for 13 weeks at doses of 0 (corn oil alone), 20, 200, and 2000 mg/kg by gavage. At the termination, all mice were euthanized with isoflurane (Mylan Inc., Tokyo, Japan) anesthesia. After necropsy, the livers were weighed and dissected. Five mice per group were selected for in vivo reporter gene mutation assays.
Reporter gene mutation assays. The protocol for the in vivo reporter gene mutation assay followed the OECD guideline for Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays (OECD, 2011). 6-thioguanine (6-TG) and Spi − selections were performed using the method of Nohmi et al. (2000) . We used DNA sample extracted from the liver of an animal that had been treated with 2-amino-3-methylimidazo [4,5-f] (48, 24 , and 3 h before the animals were terminated) at doses of 0 (corn oil alone), 500, 1000, and 2000 mg/kg by gavage to both sexes of both genotypes. As a positive control for the micronucleus assay and the comet assay, EMS was administered for 2 days (24 and 3 h before the animals were terminated) at 200 mg/kg by gavage to both sexes of both genotypes. Three hours after the final dosing, all mice were euthanized under isoflurane anesthesia. After complete necropsy, the livers were weighed and dissected for the comet assay and the bone marrows were excised for the micronucleus assay.
Comet assay in the liver. The experimental procedure basically conformed to the JaCVAM protocol for international validation study (JaCVAM, 2009) . Cell suspensions from the livers were mixed with 0.5% low-melting point agarose (NuSieve GTG Agarose, Lonza Rockland Inc., Basel, Switzerland) and deposited on Matsunami adhesive silane (MAS)-coated slide glass (Matsunami Glass Ind. Ltd, Osaka, Japan). After electrophoresis, we stained the cells with SYBR gold (Life Technologies, Carlsbad, CA) and analyzed using a fluorescent microscope connected to a comet image analyzer (comet assay IV, Perceptive Instruments Ltd, Suffolk, UK). For each sample, 100 cells (50 cells/slide) were analyzed to calculate the percentage of DNA in the tail (% Tail DNA). Heavily damaged cells, commonly referred to as "hedgehogs" (showing small or nonexistent head and largely diffused tail) were excluded from the comet data collection. Hedgehog cells were separately scored for 100 cells (50 cells/slide), and the frequency of hedgehogs was calculated.
Micronucleus assay in the bone marrow. Cells were collected from the bone marrow using fetal bovine serum (SigmaAldrich, St. Louis, MO) and were smeared on slide glass. After drying, the cells were fixed in methanol, and the slides were stored at room temperature. The cells were stained with acridine orange solution and immediately observed by fluorescence microscopy. Micronucleated polychromatic erythrocytes (MNPCEs) were recorded based on the observation of 2000 polychromatic erythrocytes (PCEs), and the MNPCE/PCE ratio was calculated. In addition, 200 total erythrocytes (PCEs + normochromatic erythrocytes) were scored for PCE frequency (PCE%).
Pathological Examination of the Liver
The remaining liver tissue samples obtained from experiments 1 and 2 were fixed in 10% buffered formaldehyde solution, embedded in paraffin wax, and stained with hematoxylineosin for histopathological examination. 
Statistical Analysis
All data were expressed as means ± SD per group. The data for body and liver weights, gpt and Spi − mutant frequencies (MFs), and parameters in comet assays were analyzed with Dunnett's multiple comparison test. The significance of differences for positive control data was analyzed with the Student-Welch test. The data for PCE ratios were analyzed with the Wilcoxon's rank sum test. The data for MNPCE/PCE ratios were analyzed with a conditional binomial test using Kastenbaum and Bowman's table (Kastenbaum and Bowman, 1970) .
RESULTS
Experiment 1
Clinical signs, body weight, liver weight, and histology of hepatocytes. No treatment-related clinical signs or deaths were detected during the 90-day-repeated administration study. Final body weights, liver weights, and histopathology in the liver are summarized in Table 1 . There were no effects on body weight or food consumption (data not shown) in animals dosed with GBE at any of the dosage levels. No macroscopic abnormalities were noted in any animals at necropsy. Relative liver weights were significantly increased in the 2000 mg/kg group. Hepatocellular hypertrophy in the centrilobular area and slight focal necrosis were observed in the 2000 mg/kg group. Table 2 . No statistically significant increase of gpt MFs was detected in the liver DNA of the GBE-treated gpt delta mice compared with those in the control group. In the analysis of Spi − selection assessing deletion mutations (Table 3) , there was no statistically significant variation in Spi − MFs values between GBE-treated and control mice.
Gene mutation assays in the liver. Data for gpt MFs analyzed by 6-TG selection are shown in
Experiment 2 Clinical signs, body weight, liver weight, and histology of hepatocytes.
In the 3-day-repeated administration study, final body weights, liver weights, and histopathological findings of livers are shown in Table 1 . There were no abnormal clinical signs and no treatment-related effects on body weight in any of the GBE-treated groups. Relative liver weight was significantly increased in male and female wild-type mice at all doses of GBE and the effect was dose dependent. In contrast, in CARKO mice of both sexes at all doses, liver weights in all the GBEtreated groups were comparable with that in the control group. Microscopically, wild-type mice in all the GBE-treated groups showed slight-to-moderate hepatocellular hypertrophy in the centrilobular area and the effect was dose dependent. In contrast, hepatocellular hypertrophy was not observed in CARKO mice, with the exception of a single animal that showed slight hepatocellular hypertrophy at the highest dose. There were no histopathological findings suggestive of cytotoxicity in the liver in any of the GBE-treated groups. Comet assay in the liver. The results of the liver comet assays are graphically summarized in Figure 1 . There was no significant difference in % Tail DNA in any of the GBE-treated groups. In the positive control group, the mean value of % Tail DNA was significantly higher than that in the control group (0 mg/kg). Hedgehogs, indicative of cytotoxic effects such as necrosis or apoptosis, were not detected in any of the animals (data not shown).
Micronucleus assay in the bone marrow. The results of the bone marrow micronucleus assays are shown in Figure 2 . There was no statistically significant change in the MNPCE/PCE ratio in any of the GBE-treated groups. In females, no significant alteration in the percentages of PCEs was seen in either genotype. In contrast, a significant decrease in the percentage of PCEs was observed in males in both genotypes, suggesting that GBE induced bone marrow toxicity in males. In the positive control group, the MNPCE/PCE ratio was significantly higher than that in the control group (0 mg/kg).
DISCUSSION
In the present study, we used several methods to investigate the in vivo genotoxicity of GBE. Using in vivo reporter gene mutation assays, no remarkable increases in gpt or Spi − MFs were observed in DNA extracted from the livers of gpt delta mice that had been exposed to GBE up to 2000 mg/kg bw/day. These results suggest that genomic mutations were not induced. Also, in the comet assay using liver, no significant increases in the % Tail DNA were detected at doses up to 2000 mg/kg, suggesting that GBE did not have the potential for inducing DNA damage. Furthermore, in the micronucleus assay, no changes in the MNPCE/PCE ratio were seen, indicating that chromosomal aberrations were not induced. In addition, GBE did not induce DNA damage or chromosomal aberrations in CARKO mice as in wild-type mice. In all of these studies, except for CARKO mice, clear liver hypertrophy was detected at the maximal dose, indicating that GBE did indeed reach the liver. In the positive control group, gpt and Spi − MFs, the % Tail DNA and the MNPCE/PCE ratio were significantly higher than those in the control group (0 mg/kg). Thus, all the exper- Note. GBE, Ginkgo biloba extract; IQ, 2-amino-3-methylimidazo[4,5-f]quinoline; Cm R , chloramphenicol-resistant; 6-TG R , 6-thioguanine-resistant; MFs, mutant frequencies.
imental trials clearly provided evidence that the present studies were conducted under appropriate conditions and that GBE was not genotoxic in vivo.
GBE is composed of a number of ingredients and constituent concentrations vary widely in commercially available GBE products (Kressmann et al., 2002) . Several ingredients in GBE are known in vitro mutagens. Quercetin, one of the principal components of GBE, was a strong mutagen in S. typhimurium with and without S9 mix (Bjeldanes and Chang, 1977; MacGregor and Jurd, 1978; Nagao et al., 1981; Resende et al., 2012) . Therefore, quercetin is considered to be one of the factors producing a positive result in the Ames assay in the NTP study of GBE. Importantly, quercetin has generally produced negative results in many in vivo studies (Aeschbacher et al., 1982; Caria et al., 1995; NTP, 1992) . Furthermore, no evidence of liver carcinogenicity was observed in a 2-year study (NTP, 1992) . From these results, the International Agency for Research on Cancer (IARC) concluded that quercetin is not classifiable as to its carcinogenicity to humans (IARC, 1999) . Additionally, quercetin is allowed for use as a food additive in Japan (Ministry of Health and Welfare, 1996) . On the basis of these international or national assessments of quercetin, concerns about the genotoxicity quercetin in GBE could be excluded. As for other compounds in GBE causing genotoxicity, ginkgolic acids were reported to induce DNA damage as measured by the comet assay in primary rat hepatocytes in vitro (Westendorf and Regan, 2000) . The standard level of GBE used in prescriptions in Germany and France is designed to limit the amount of ginkgolic acids to 5 ppm or less, due to their mutagenic, cytotoxic, and allergenic potential (Kressmann et al., 2002) . GBE used for our study contained 10.45 ppm ginkgolic acids, a concentration higher than recommended (NTP, 2013) . Nevertheless, this level of GBE showed no genotoxic effects in the present study. Our results suggest that commercially available GBE products within the recommended level of ginkgolic acid do not have the potential for genotoxicity in vivo. Three-day treatment showed a clear relationship between CAR and GBE. In wild-type mice, GBE induced liver weight increases and hepatocellular hypertrophy. In CARKO mice, hepatocellular hypertrophy was not detected in most GBE-treated animals. These results indicate that CAR was involved in GBEinduced liver hypertrophy. GBE is a known inducer of xenobiotic metabolizing enzymes through activation of CAR, pregnane X receptor (PXR), and aryl hydrocarbon receptor (AHR) in human HepG2 cells (Li et al., 2008) and mice (Umegaki et al., 2007) . In the present study, GBE induced slight hepatocellular hypertrophy in one animal in the 2000 mg/kg group in CARKO male mice, suggesting the involvement of other nuclear receptors such as PXR or AHR.
For nongenotoxic hepatocarcinogens, several carcinogenic modes of action (MOA) have been identified that act through nuclear receptors-mediated mechanism (Budinsky et al., 2014; Corton et al., 2014; Elcombe et al., 2014) . Among them, a MOA for CAR-mediated liver tumor formation has been well studied. Phenobarbital (PB) is a nongenotoxic indirect CAR activator and induces liver tumors in mice and rats (Holsapple et al., 2006; Whysner et al., 1996) . The key events in the PB-induced liver tumor MOA comprise activation of CAR, increased cell proliferation and formation of altered hepatic foci, and eventually the development of liver tumors (Elcombe et al., 2014; Holsapple et al., 2006) . Although PB induces liver tumors in rodents, epidemiologic studies of patients undergoing long-term PB therapy showed no increase in the incidence of hepatic cancer in humans (IARC, 2001; Lamminpää et al., 2002) . Hence, it is commonly believed that CAR-mediated carcinogenic MOA similar to PB are not likely relevant to humans (Holsapple et al., 2006) . For that reason, we have undertaken a hepatocarcinogenesis study using CARKO mice to clarify whether CAR is involved in liver carcinogenesis by GBE. If GBE-induced liver carcinogenesis is CAR mediated in this study, then it can be concluded that its hepatocarcinogenic potential is not relevant to humans.
In conclusion, the present study demonstrates that GBE does not have the potential for genotoxicity in vivo, indicating that GBE-induced hepatocarcinogenesis in mice occurs through a non-genotoxic MOA.
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